NCT04095013View on ClinicalTrials.gov

Intrathecal Bupivacaine-fentanyl and Bupivacaine-dexmedetomidine for Elective Low Segment Caesarean Section

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

June 15, 2019

Study Completion Date

July 15, 2019

Conditions
Cesarean Section Complications
Interventions
DRUG

Bupivacaine, fentanyl

Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,

DRUG

Bupivacaine, dexmedetomidine

Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms

Trial Locations (2)

75520

Civil Hospital Karachi, Karachi

DUHS, Civil hospital Karachi (CHK), Karachi

All Listed Sponsors
lead

Dow University of Health Sciences

OTHER

NCT04095013 - Intrathecal Bupivacaine-fentanyl and Bupivacaine-dexmedetomidine for Elective Low Segment Caesarean Section | Biotech Hunter | Biotech Hunter